Affordable Access

deepdyve-link
Publisher Website

Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction.

Authors
  • Chouhan, Jay1
  • Gupta, Rohan1
  • Ensor, Joe2
  • Raghav, Kanwal3
  • Fogelman, David3
  • Wolff, Robert A3
  • Fisch, Michael4
  • Overman, Michael J3
  • 1 Department of Internal Medicine, The University of Texas Health Sciences Center, Houston, Texas.
  • 2 Houston Methodist Cancer Center, Houston Methodist Research Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 3 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 4 Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Type
Published Article
Journal
Cancer Medicine
Publisher
Wiley
Publication Date
Feb 01, 2016
Volume
5
Issue
2
Pages
239–247
Identifiers
DOI: 10.1002/cam4.587
PMID: 26714799
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Malignant small bowel obstruction (MSBO) that does not resolve with conservative measures frequently leaves few treatment options other than palliative care. This single-institution retrospective study assesses the outcomes of a more aggressive approach-concurrent systemic chemotherapy and total parenteral nutrition (TPN)-in the treatment of MSBO. The MD Anderson pharmacy database was queried to identify patients who received concurrent systemic chemotherapy and TPN between 2005 and 2013. Only patients with MSBO secondary to peritoneal carcinomatosis requiring TPN for ≥8 days were included. Survival and multivariate analyses were performed using the Kaplan-Meier method and Cox proportional hazard models. The study included 82 patients. MSBO resolution was observed in 10 patients. Radiographic assessments showed a response to chemotherapy in 19 patients; 6 of these patients experienced MSBO resolution. Patients spent an average of 38% of their remaining lives hospitalized, and 28% of patients required admission to the intensive care unit. In multivariate modeling, radiographic response to chemotherapy correlated with MSBO resolution (odds ratio [OR] 6.81; 95% confidence interval [CI], 1.68-27.85, P = 0.007). Median overall survival (OS) was 3.1 months, and the 1-year OS rate was 12.6%. Radiographic response to chemotherapy (HR 0.30; 95% CI, 0.16-0.56, P < 0.001), and initiation of new chemotherapy during TPN (HR 0.55; 95% CI, 0.33-0.94, P = 0.026) independently predicted for longer OS. Concurrent treatment with systemic chemotherapy and TPN for persistent MSBO results in low efficacy and a high morbidity and mortality, and thus should not represent a standard approach. © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times